Personalized Neoantigen mRNA Cancer Vaccine Succeeds in Phase III, Cutting Melanoma Recurrence or Death Risk by 42%

A personalized neoantigen mRNA cancer vaccine met its primary endpoint in a Phase III melanoma trial, further reducing the risk of recurrence or death by 42% on top of pembrolizumab (Keytruda). The source describes this as the first personalized neoantigen therapy with a positive Phase III result worldwide and the first positive Phase III result in the mRNA cancer treatment field. The republished text does not disclose the specific vaccine name, trial name, sample size, HR, or CI.